Acquiring Company
Faeth Therapeutics
Acquired Company
Faeth Therapeutics
AustinAustinBiotechnologyHealth CareMedicalTherapeuticsresearchBiotechnologyHealth CareMedicalTherapeuticsresearchDescription
Sensei Biotherapeutics has acquired Faeth Therapeutics, enabling it to integrate Faeth’s lead asset PIKTOR into its clinical pipeline. The acquisition is accompanied by a $200 million private placement to fund key clinical milestones in targeted cancers. Sensei aims to advance pivotal trials for treating endometrial and breast cancer.
Who to call at Faeth Therapeutics, and when
When Faeth Therapeutics changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Faeth Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Faeth Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Faeth Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Faeth Therapeutics makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Faeth Therapeutics?
Faeth Therapeutics was acquired by Faeth Therapeutics, based in Austin. The deal was reported on February 18, 2026. Rather the company is aiming to interrogate how nutrition can become a “fifth pillar” of cancer care through scientific study. The company also has another trial aimed at metastatic colorectal cancer. Faeth Therapeutics is publicly traded (FTH) and operates in Biotechnology.
When did Faeth Therapeutics acquire Faeth Therapeutics?
Faeth Therapeutics's acquisition of Faeth Therapeutics was reported on February 18, 2026. Sensei Biotherapeutics has acquired Faeth Therapeutics, enabling it to integrate Faeth’s lead asset PIKTOR into its clinical pipeline. The acquisition is accompanied by a $200 million private placement to fund key clinical milestones in targeted cancers. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Faeth Therapeutics do?
Rather the company is aiming to interrogate how nutrition can become a “fifth pillar” of cancer care through scientific study. The company also has another trial aimed at metastatic colorectal cancer. It is publicly traded (FTH), operating in Biotechnology, and is based in Austin.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.